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Abstract
Background: C-C chemokine receptor (CCR)7 is a regulator of dendritic cell and T cell migration, and its role in
tissue wound healing has been investigated in various disease models. We have previously demonstrated that
CCR7 and its ligand, chemokine (C-C motif) ligand (CCL)21, modulates wound repair in pulmonary fibrosis (PF) but
the mechanism of this is unknown. The objective of this study was to investigate whether the absence of CCR7
protects against bleomycin (BLM)-induced PF. CCR7
-/- mice failed to mount a fibrotic pulmonary response as
assessed by histologic collagen staining and quantification by hydroxyproline. We hypothesized that the prominent
characteristics of CCR7
-/- mice, including elevated levels of cytokine and chemokine mediators and the presence of
bronchus-associated lymphoid tissue (BALT) might be relevant to the protective phenotype.
Results: Pulmonary fibrosis was induced in CCR7
+/+ and CCR7
-/- mice via a single intratracheal injection of BLM.
We found that the lung cytokine/chemokine milieu associated with the absence of CCR7 correlated with an
increase in BALT, and might be attributable to regulatory T cell (Treg) homeostasis and trafficking within the lungs
and lymph nodes. In response to BLM challenge, CCR7
-/- mice exhibited an early, steady increase in lung CD4
+ T
cells and increased CD4
+ CD25
+ FoxP3
+ Tregs in the lungs 21 days after challenge. These findings are consistent
with increased lung expression of interleukin-2 and indoleamine 2,3-dioxygenase in CCR7
-/- mice, which promote
Treg expansion.
Conclusions: Our study demonstrates that the protective phenotype associated with BLM-treated CCR7
-/- mice
correlates with the presence of BALT and the anchoring of Tregs in the lungs of CCR7
-/- mice. These data provide
novel evidence to support the further investigation of CCR7-mediated Treg trafficking in the modulation of BLM-
induced PF.
Introduction
Idiopathic pulmonary fibrosis (IPF) is an irreversible, fatal
lung disease, marked by progressive deterioration of lung
function due to an uncontrolled repair process [1]. The
pathogenesis of IPF is not completely understood, which
is reflected in the lack of successful treatments and good
diagnostic markers. Although it is generally accepted that
IPF comprises an inflammatory and regenerative phase
that results in excessive collagen deposition distorting
normal lung architecture and function, the importance of
inflammation in fibrosis has been challenged [2]. The
majority of investigations aimed at dissecting the patho-
genesis of fibrosis have been conducted in animal models,
w h i c hh a v es t r o n g l ys u g g e s t e dt h a tt h ed y s r e g u l a t e d
healing process is sustained by chronic inflammation [3].
The inflammatory cells recruited to the lung and the fac-
tors they secrete dictate the nature, duration and severity
of the inflammatory response. Chemokines and chemo-
kine receptors are the primary regulators of the inflam-
matory cells that are (1) recruited to sites of injury (2)
elicit wound-healing responses from the tissue resident
cells.
C-C chemokine receptor (CCR)7 is a chemokine
receptor that is expressed strongly on mature dendritic
cells (DCs), naive and memory T cells, fibrocytes and
structural cells comprising the fibroblastic foci in the
lungs of patients with IPF [4-6]. The CCR7 ligands, che-
mokine (C-C motif) ligand (CCL)19 and 21, are consti-
tutively expressed in the secondary lymphoid organs and
lymphatic vessels, and are central to the homing and
trafficking of T cells. CCR7 expression allows these cells
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in response to antigen stimulation and suppress effector
cell responses. The T cells traditionally associated with
attenuating immune cell activation are the T regulatory
cells (Tregs), but their role in fibrotic responses is not
clear. The importance of CCR7 in proper Treg mobiliza-
tion has been demonstrated by studies showing that
Tregs lacking CCR7 accumulate in the lung and fail to
traffic to the LNs [7,8].
We have previously demonstrated that CCR7 and
CCL21 are key regulators in the pathogenesis of PF
[6,9,10]. In the study we report here, we targeted CCR7
in a bleomycin (BLM) model of PF, which has been use-
ful in dissecting the roles of the chemokine/cytokine
network in both the inflammatory and fibrogenic phases
of lung fibrosis. We conducted our investigation in the
CCR7
-/- mouse, which possesses bronchus-associated
lymphoid tissue (BALT) and demonstrates impaired
homing of Tregs [7,8]. BALT is often described as a ter-
tiary lymphoid tissue rich in B and T cells. Although its
exact function is not clearly understood, several murine
studies have implicated BALT in facilitating primary
immune responses via local priming of lymphocytes and
in serving as a reservoir for viruses during their latency
period [11,12]. The importance of lymphocytes in the
pathogenesis IPF remains controversial; however, lym-
phocyte infiltration in areas of active fibroblastic prolif-
e r a t i o ni nt h eI P Fh a v eb e e ni d e n t i f i e da n ds h o w nt o
exhibit an elevated CD4/CD8 T cell ratio that correlates
positively with survival of these patients [13-15].
In this study, we hypothesized that CCR7
-/- mice
would be protected from the deleterious pulmonary
effects of BLM. We assessed the histologic effects of
BLM in the lungs, and investigated the chemokine/cyto-
kine milieu in the lungs of wild type (WT) and CCR7
-/-
mice. Our data suggest that the increased levels of
inflammatory cell infiltrates in the BALT of CCR7
-/-
mice may protect against fibrosis. Further, these infil-
trates correlated with the impaired trafficking of Tregs
between the lungs and LNs during the inflammatory
and fibrogenic phases of BLM-induced PF. We found
Tregs accumulating in the lungs of both CCR7 gene-
deleted mice. Our data support the further investigation
of the underappreciated role of T cells and inflammation
in the pathogenesis and maintenance of PF.
Results
BLM-induced PF is diminished in CCR7
-/- mice compared
with WT
In the present study, we investigated whether the
absence of CCR7 affects the development of PF in a
murine model. WT (CCR7
+/+) and CCR7
-/- mice
received a single intratracheal injection of BLM on day
0, and we compared the degree of fibrosis in the lungs
21 days later. Similar to previous reports [16], histologic
analysis indicated severe lung fibrosis in BLM-treated
WT mice, as evidenced by complete distortion of nor-
mal lung architecture, interstitial thickening, fibroblastic
proliferation and abundant Masson-trichrome staining
for collagen, (Figure 1A panel a). This effect was not
seen in the lungs of BLM-treated CCR7
-/- mice, which
had significantly less histologic fibrosis (Figure 1A panel
b). The lungs of BLM-treated CCR7
-/- mice, analyzed at
day 21, exhibited decreased staining for collagen and
retention of the integrity of the alveolar space (Figure
1Ae, 1Af). These histologic differences were confirmed
by the quantification of hydroxyproline, an index of
total lung collagen and fibrosis: on day 21 after BLM
injection, the lungs of CCR7
-/- mice had significantly
less collagen-associated hydroxyproline compared with
those of WT mice (Figure 1B).
Expansion of BALT occurs in the lungs of BLM-treated
CCR7
-/- mice during the early inflammatory phase
CCR7
-/- mice have been previously described as posses-
sing highly organized BALT and severely reduced num-
bers of Tregs in the lung-draining (bronchial) (br)LNs
[8]. Figure 1A confirms the presence of BALT localized
to the main bronchi and arteries (black arrows), as pre-
viously described in CCR7-deficient mice (Figure 1Ab)
which was absent in untreated WT mice (Figure 1Aa)
[8]. We next analyzed lung histopathology in BLM-trea-
ted mice to determine whether histologic changes occur
in the BALT within the first 7 days after the BLM insult.
Hematoxylin and eosin staining of lung tissue obtained
from mice at day 7 after BLM injection indicated that
WT lungs demonstrate a typical robust inflammation in
the alveolar space (Figure 1Ac), which appeared aug-
mented in the lungs of CCR7
-/- mice because of the
apparent expansion of the lymphoid tissue surrounding
the bronchi (Figure 1Ad). Interestingly, BALT in the
lungs of CCR7
-/- mice did not appear to be in an
expanded state by day 21 after BLM injection (Figure
1Af), suggesting that the pulmonary inflammation in
CCR7
-/- mice is tightly regulated despite the constitutive
presence of immune cell aggregates.
To test whether the histologic differences observed
between WT and CCR7
-/- mice (Figure 1) correlate with
differences in the production of inflammatory mediators,
we next quantified both Th1 and Th2 pro- and anti-
inflammatory cytokines in whole lung homogenates by
ELISA 21 days after BLM injection. Interestingly, the
data demonstrated that even before BLM challenge,
untreated (day 0) CCR7
-/- mouse lung homogenates
exhibited an overall striking increase in Th1- and Th2-
associated cytokines and chemokines compared with
untreated WT lungs (Figure 2). Although the differences
did not reach significance, the overall trend was
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Page 2 of 9Figure 1 CCR7
-/- mice exhibit decreased collagen deposition in response to bleomycin. (A) Representative histologic sections of mouse
lungs. Mouse lung from (a) wild type (WT) and (b) C-C chemokine receptor (CCR)7
-/- mouse 21 days after bleomycin treatment. Masson-
trichrome stain. (B) Hydroxyproline levels in whole lung homogenates from untreated or bleomycin-challenged mice. Data are mean ± SEM
from four to five mice at each time point, and are representative of three separate experiments. **P < 0.01.
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These data correlate with the presence of BALT in
untreated (day 0) CCR7
-/- mice (Figure 1Ab). By day 21
after BLM injection, protein levels in CCR7
-/- lungs
were comparable or lower than those measured in the
WT lungs, with the exception of interleukin (IL)-12 and
macrophage inflammatory protein (MIP)1a, which are
slightly increased in CCR7
-/- lung homogenates com-
p a r e dw i t hW Tl u n g sa n dh a v eb e e ni m p l i c a t e di n
BLM-induced PF. No significant differences were
detected in the levels of inflammatory mediators
between WT and CCR7
-/- mouse lungs on day 21 after
BLM injection, suggesting that CCR7
-/- mice do have
increased production of pro- or anti-inflammatory med-
iators. Taken together, these data indicate that the pro-
tective phenotype exhibited by CCR7
-/- mice is not
related to an increased inflammatory response after
BLM injection, but is possibly due to an increase in the
lymphocyte population in the lung that is localized
within the BALT.
Intrapulmonary fibrocyte recruitment is unchanged in
BLM-treated CCR7
-/- mice
The recruitment of fibrocytes to the lung during inflam-
mation has been documented as an important factor in
the development of PF, and is mediated, in part, by
CCR7 and its ligand, CCL21 [17,18]. We next deter-
mined whether fibrocyte recruitment to the lung was
altered in CCR7
-/- mice compared with WT mice during
the peak inflammatory phase of BLM-induced PF. In
line with the methods of previous studies, we quantified
the percentage of Col 1
+ CD45
+ cells in whole lung
homogenates from WT and CCR7
-/- mice 7 days after
BLM challenge, to determine the number of fibrocytes
present in the lung during the peak inflammatory phase
of BLM-induced injury. BLM increased the number of
intrapulmonary fibrocytes to a similar extent in WT and
CCR7
-/- mice (Figure 3), suggesting that the attenuated
fibrotic response in BLM-treated CCR7
-/- mice was
independent of fibrocyte recruitment to the lung and




+ cells are present in lungs of CCR7
-/-
mice but absent in WT mice during the fibrotic stage of
BLM-induced injury
Distinct T cell areas have been described in BALT,
which have been identified as having an important role
in DC interactions and cytokine production [19-21].
Because we observed an expansion of BALT in the
lungs of CCR7
-/- mice, we next determined the T
Figure 2 Global Increase in inflammatory mediators observed in lungs of untreated CCR7
-/- mice. ELISA analysis of (A) interferon (IFN)g,( B)
C10, (C) IFN-inducible protein (IP)-10, (D) monocyte chemotactic protein (MCP)-1, (E) interleukin (IL)-10, (F) tumor necrosis factor-a,( G) IL-12, (H)
monocyte chemotactic protein (MIP)1-a,( I) chemokine (C-C motif) ligand (CCL)17, (J) IL-4, (K) CXC chemokine ligand (CXCL)1, (L) transforming
growth factor-b and (M) IL-13 in whole lung homogenates from untreated wild type (WT) and C-C chemokine receptor (CCR)7
-/- mice and in WT
and CCR7
-/- mice at day 21 after bleomycin challenge. Data are mean ± SEM from four to five mice at each time point. *P < 0.1).
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LNs after BLM challenge. Analysis of total CD4
+ cells
indicated a steady increase in their percentage in the
lungs of CCR7
-/- mice during the peak inflammatory
response after BLM injection (Figure 4A). This trend
was not observed in the lungs of WT mice at the same
time points, (that is, days 1, 3 and 7 after BLM injec-
tion) (Figure 4A). At day 21 after BLM injection, a
decrease in CD4
+ cells was observed in the lungs of
both WT and CCR7
-/- mice, but the percentage of
CD4
+ cells in CCR7
-/- lungs still exceeded that in WT
lungs (Figure 4A). Previous studies have demonstrated
that mice deficient in CCR7 exhibit a significant reduc-
tion in the numbers of Tregs in the lung-draining LNs
and impaired homing of Tregs into secondary lymphoid
organs [8]. Therefore, we next investigated whether dif-
ferences in Treg numbers between WT and CCR7
-/-
lungs at day 21 correlated with the histologic differences
observed (Figure 1). One day after BLM injection, we
detected fewer Tregs (CD4
+CD25
hi+FoxP3
+) in the lungs
of CCR7
-/- mice compared with WT; however, through-




+ cells was similar in
both WT and CCR7
-/- mice (Figure 4B). By contrast,
21 days after BLM injection, Tregs were not detected in
the lungs of WT mice, but were maintained at low
levels in CCR7
-/- mice (Figure 4B). Localization of
FoxP3-expressing Tregs in the BALT of CCR7
-/- mice
was confirmed by immunohistochemistry (data not
shown). Furthermore, we determined that on day 21,
gene transcript expression of the Treg-promoting
mediators, IL-2 (Figure 4E) and indoleamine 2,3 dioxy-
genase (IDO) (Figure 4F), were also increased in the
lungs of CCR7
-/- mice compared with WT.
CCR7 expression by T cells mediates their trafficking
between the lung and draining LN, where expansion
and maintenance of the T cell memory pool occurs. In a
murine model of allergic airway inflammation, CCR7
was shown to control the exit of T cells from peripheral
tissues and entry into afferent lymphatics [22]. To deter-
mine whether the lack of CCR7 localized T cells to the
lungs of CCR7
-/- mice and prevented the exit into the
draining LNs, we examined the accumulation of T cells
in the lung draining brLNs in WT and CCR7
-/- mice
during the inflammatory phase (days 3 and 7) and the
fibrotic phase (day 21) after BLM injection. The percen-
tages of CD4
+ cells on days 3 and 7 after BLM injection
were less in the brLNs from CCR7
-/- mice compared
with WT, although by day 21 the percentage of CD4
+
cells in the brLN of CCR7
-/- mice exceeded that of WT
(Figure 4C). These data were not surprising because
CCR7 has been identified as a required homing receptor
for T cell exit from the lung and entry to the draining
lymphatics [22]. CCR7 has also been shown to be
important for the migration of Tregs into the peripheral
LNs, where they proliferate and exert effector cell func-




+ Tregs in the lungs of BLM-
treated CCR7
-/- mice on day 21, which were undetect-
able in the lungs of BLM-treated WT mice, indicating
that the absence of CCR7 contributes to the retention of
Tregs in the inflamed lung. Interestingly, we also
detected Tregs in the brLNs of BLM-treated CCR7
-/-
mice (Figure 4D), suggesting that an alternative mechan-
ism functions to localize Tregs in the LN in the absence
of CCR7.
Discussion
The purpose of our study was to determine whether the
a b s e n c eo fC C R 7a t t e n u a t e dP Fi nm i c et h a tw e r ec h a l -
lenged intratracheally with BLM. We report that
CCR7
-/- mice have decreased sensitivity to BLM-induced
injury in the lung because they fail to exhibit the severe
pulmonary remodeling typically associated with BLM-
induced PF. In this study we present a complete profile
of cytokine expression in WT and CCR7
-/- mice at base-
line and after BLM challenge, and an examination of
fibrocytes and immune cells into the lung. Although we
acknowledge that significant differences were not quan-
tifiable under our experimental conditions, we are confi-
dent about the striking, reproducible trends we have
observed.
Although CCR7 is strongly expressed in various bone
marrow-derived cells, most notably DCs, we focused our
study on T cell trafficking in BLM-induced PF because
Figure 3 Fibrocyte recruitment to the lungs in bleomycin-
treated WT and C-C chemokine receptor (CCR)7
-/- mice. Flow
cytometry analysis of fibrocytes in whole lungs of wild type (WT)
and CCR7
-/- mice 7 days after bleomycin challenge. Cells were
immunostained with phycoerythrin (PE)-conjugated anti-mouse
CD45 and biotin-conjugated anti-mouse collagen 1 and
allophycocyanin-labeled strepavidin. Data shown are the
percentages of collagen 1+ cells of total CD45+ population from
five mice in each group.
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-/- mice is the pre-
sence of BALT in their lungs. BALT is a tertiary lym-
phoid structure that functions as a local reservoir for
priming T lymphocytes and is involved in the impaired
homing of Tregs in CCR7
-/- mice [7,8,12]. We observed
that the BALT in CCR7
-/- mice was altered during the
course of BLM-induced injury, and may represent the
dynamics of Treg traffickingd u r i n gB L M - i n d u c e dp u l -
monary remodeling.
Treg cells represent a conservative 1-10% of total CD4
+
T cells, yet their immunosuppressive functions are
indispensable for immune homeostasis [23]. Our study
demonstrates that Treg-promoting genes (IL-2 and IDO)
are upregulated in the lungs of BLM-treated CCR7
-/-
mice, which suggests that the lung environment
in CCR7
-/- mice is favorable to the maintenance of




+ Treg cells are retained in the lungs
of BLM-treated CCR7
-/- mice, which is consistent with
an ameliorated remodeling response to BLM-induced
injury in the lung. Preliminary studies using CCR7
-/-
bone-marrow chimeras confirmed the localization of
CCR7
-/- Tregs to the lung, which we consider is due to a
CCR7 deficiency in hematopoietic cells and not to altered
functions of the structural cells within the lungs of
CCR7
-/- mice (GT, AJH, CMH, unpublished data). These
ongoing studies also indicated an appreciable increase in
the total number of CD4
+ cells in the lungs of chimeric
mice (CCR7
-/-®WT) during the fibrotic phase at 21 days
after BLM injection (GT, AJH, CMH, unpublished data),
which is consistent with that in the intact CCR7 knock-
out mice. The Treg population in the lungs of chimeric
mice (CCR7
-/-®WT) was also increased compared with
WT controls (WT®WT), an effect previously observed
in BLM-treated CCR7
-/- mice, and Tregs were present in
the LNs of CCR7
-/- chimeric mice 21 days after BLM
injection challenge. Taken together, our results present
novel evidence for an underappreciated role for CCR7
in the context of Treg trafficking during the pathogenesis
of PF.
We observed an increase of BALT in the lungs of
CCR7
-/- during BLM-induced PF and we believe that
this promotes protection from BLM-induced PF. Ter-
tiary lymphoid structures in the lung have been impli-
cated in providing sustained protective immunity to
viruses and chronic asthma, and in lung cancers, tumor-
induced BALT has been associated with increased survi-
val [11,21,24]. Similarly, lymphoid aggregates resembling
lymphoid follicles have been identified in fibrosing dis-
eases, including IPF [25-27], although its exact function
a n do r i g i ni sn o tk n o w n .W ef o u n dt h a tt h eB A L Ti sa
dynamic structure within the lungs of CCR7
-/- mice,
and its function during BLM-induced PF may be related
to the retention of Tregs in the lung.
A recurring observation in our study that warrants
further investigation is CCR7-independent trafficking dur-
ing PF. Firstly, CCR7 has been widely shown to function
as a potent stimulus for chemotaxis of bone marrow-
derived Col 1-positive cells (fibrocytes) [18]. Our study did
not indicate significant diminution of fibrocytes in BLM-
treated CCR7
-/- mice despite their protection from fibrosis.
These data were not entirely surprising, because recruit-
ment of fibrocytes to murine lungs has been shown to be
mediated by other receptors including chemokine CXC
motif receptor (CXCR)4, CCR2 and CCR5 [28-30].
Figure 4 Absence of CCR7 is associated with pulmonary
localization of CD4+, CD4+CD25+FoxP3+ and CD8+ T cells.( A,
B) Lung cells and (C, D) bronchial lymph node cells from wild type
(WT) and C-C chemokine receptor (CCR)7
-/- mice 1,3,7 and 21 days
after bleomycin challenge were stained with (A, C) phycoerythrin
(PE)-cyanin (Cy)7-conjugated anti-CD4 or (B, D)PE-conjugated anti-
CD25 and PE-Cy5-conjugated anti-forkhead box (FOX)P3. CD4+CD25
+FOXP3 T cells are expressed as percentage of total cells. n = three
to mice/group/experiment. Samples were individualized except in
those from the bronchial lymph nodes (brLNs) on days 3 and 21, in
which cells from three to five mice were pooled. These data are
representative of two separate experiments. TaqMan PCR analysis of
whole lung samples for (E) interleukin (IL)-2 and (F) indoleamine 2,3
dioxygenase (IDO) transcript expression 21 days after bleomycin
challenge. Transcript expression was compared with that before the
intratracheal (IT) bleomycin challenge (that is, day 0). All data are
shown as the expression fold difference from three to five mice at
each time point after i.t. bleomycin challenge. SEM from four to five
mice at each time point. ***P < 0.001. ND = not detected; NS = not
significant.
Trujillo et al. Fibrogenesis & Tissue Repair 2010, 3:18
http://www.fibrogenesis.com/content/3/1/18
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receptors in our system, it is plausible that they may func-
tion as a compensatory mechanism to recruit fibrocytes to
the lungs of CCR7
-/- mice. Moreover, we cannot discount
the possibility that fibrocyte proliferation in the lung may
also account for the comparable levels of fibrocytes
observed in WT and CCR7
-/- mice.
Second, contrary to our expected results and those pre-
viously reported by Kocks et al., we consistently detected
relatively high levels of CD4
+CD25
hi+FoxP3
+ Tregs in the
brLN of CCR7
-/- mice on days 3 and 7, and in fact a






-/- mice (compared with WT) 21 days after
BLM injection. These results could be indicative of com-
pensatory, CCR7-independent mechanisms that regulate
the trafficking of Tregs from the lungs to the brLNs.
Such mechanisms have been proposed in the context of
the trafficking of CD4
+ T cell to the brLNs of CCR7-defi-
cient mice during influenza infection, the presence of
CD11b
+CD11c
+ DCs in the mediastinal LNs of CCR7-
deficient mice during the late phase of Mycobacterium
tuberculosis infection, and the homing of central memory
CD8
+ T cells to peripheral LNs in plt/plt (CCL19 and
CCL21-Ser-gene deleted) mice [31-33]. In addition, Zou
et al. previously demonstrated that human CD4
+CD25
+
Tregs traffic and are retained in the bone marrow
through CXCR4/CXCL12 (CXC chemokine ligand 12)
[34]. Therefore, we cannot exclude the possibility that
our detection of CD4
+CD25
hi+FoxP3
+ Tregs in brLNs of
BLM-treated CCR7
-/- mice in this study is related to
these CCR7-independent pathways.
During the preparation of this manuscript, a study by
Kotsianidis et al. was published, which reported a dramatic
decrease in the number and function of Tregs in both
bronchoalveolar lavage and peripheral blood from patients
with IPF [35]. The data presented in our current study
contribute to the current understanding of the role of
Tregs during PF. T cell expansion has clinical potential for
treating a variety of diseases such as autoimmunity and
chronic asthma, and can be manipulated to promote graft-
specific tolerance during organ transplantation. Therapeu-
tic injections of IL-2 monoclonal antibodies have been
shown to expand the Treg population in vivo without
inducing proliferation of CD8
+ and NK cells [36]. More-
over, therapeutic transfer of regulatory T cells prevents
development of allergic airway remodeling [37]. Our study
provides a rationale for targeting CCR7 in IPF and for the
further investigation of therapies to favor the expansion
and retention of the Treg population in the IPF lung.
Conclusions
The data presented in this study indicate a potential pro-
tective role for BALT and retention of Tregs in the lung
during BLM-induced PF. We found that CCR7 is linked to
Treg cell trafficking and the amelioration of BLM-induced
PF. These data provide a rationale for further studies
investigating CCR7 and the regulation of Treg trafficking
as potential therapeutic targets against IPF.
Methods
The Animal Use Committee at the University of Michi-
gan (Ann Arbor, MI, USA) approved all protocols and
experiments described in this report.
Mice
Specific-pathogen-free male C57BL/6 (WT; CCR7
+/+)
mice (6 to 8 weeks of age) were purchased from Taco-
nic (Germantown, NY, USA). CCR7
-/- mice were gener-
ated as previously described[38], and were bred and
housed under specific pathogen-free conditions.
BLM model of pulmonary inflammation and fibrosis
WT (CCR7
+/+), CCR7
-/- mice, or bone-marrow chimeras
were given 0.05 U of sterile BLM sulfate (Blenoxane,
Bristol-Meyers Pharmaceuticals, Evansville, IN, USA)
dissolved in phosphate-buffered saline (approximately
1.7 U/kg body weight) via an intratracheal injection.
Groups of WT (CCR7
+/+), CCR7
-/- mice (n = 5-10 per
timepoint) and bone-marrow chimeras were monitored
for survival. Mice in other groups were killed and their
lung tissues analyzed at days 1, 3, 7 and 21 after BLM
injection. Untreated mice (n = 5) did not receive BLM,
and this time point was designated as day 0.
Hydroxyproline assay
Left lobe samples from WT (CCR7
+/+)a n dC C R 7
-/-
mice (n = 5 per group for each time point in each
experiment) before (that is, day 0) and at day 21 after
BLM challenge were analyzed for hydroxyproline using
a previously described assay [16,39].
Cytokine and chemokine ELISA analysis
Screening for the chemokines/cytokines C10, interferon
(IFN)-g,I F N - i n d u c i b l ep r o t e i n-10, monocyte chemotac-
tic protein (MCP)-1, macrophage inflammatory protein
(MIP)1a, IL-4, IL-10, IL-12, IL-13, CCL17, CXCL1,
tumor necrosis factor-a and transforming growth fac-
tor-b was carried out on 50 μl samples of cell-free
supernatants from whole lung homogenates using a
standardized sandwich ELISA technique (R&D Systems,
Minneapolis, MN, USA). Cytokine and chemokine levels
in each sample were normalized to the protein present
in cell-free preparation of each sample, as measured by
the Bradford protein assay.
Flow cytometry analysis
Lung cells were isolated after collagenase dispersion to
obtain single-cell suspensions, as previously described
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were prepared by isolation of bronchial LNs, pushing
cells through a 40 μm nylon mesh using a syringe. Cells
were stained with the indicated antibodies after 5 min of
preincubation with Fc receptor blocking reagent
( F cB l o c k ;B DB i o s c i e n c e s ,S a nJ o s e ,C A ,U S A )f i x e d
overnight with 4% formalin and run on a Cytomics FC-
500 (Beckman Coulter, Brea, CA, USA). Samples were
analyzed using FlowJo software (Tree Star, Inc., Ashland,
OR, USA).
Real-time TaqMan PCR analysis
Total RNA was prepared from whole lung samples using
TRIzol reagent according to the manufacturer’s direc-
tions (Invitrogen, Carlsbad, CA, USA). A total of 1.0 μg
from whole lung RNA was reverse transcribed into
cDNA using Moloney murine leukemia virus reverse
transcriptase as described previously (Invitrogen) [16].
TaqMan gene expression reagents were used to assay
IL-2 and IDO (Applied Biosystems, Foster City, CA,
USA). Whole lung gene expression in WT (CCR7
+/+)
and CCR7
-/- mice was expressed as a fold increase in
transcript expression in BLM-challenged lung compared
with unchallenged lung. The fold difference in mRNA
expression between treatment groups was determined
by software developed by Applied Biosystems.
Statistical analysis
All results are expressed as mean ± SEM. The means
between groups at different time points were compared
by two-way ANOVA. Individual differences were further
analyzed using the unpaired t-test with Welch correc-
tion or the Tukey-Kramer multiple comparisons test
where indicated. Values of P <0 . 1 * ,P <0 . 0 1 * *a n d
P < 0.001*** were considered significant.
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